PMID- 36114118
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230610
IS  - 2531-1387 (Electronic)
IS  - 2531-1379 (Print)
IS  - 2531-1379 (Linking)
VI  - 45
IP  - 2
DP  - 2023 Apr-Jun
TI  - Immediate adverse events to intravenous immunoglobulin in pediatric patients with 
      inborn errors of immunity: A longitudinal study with a pre-infusion protocol.
PG  - 253-258
LID - S2531-1379(22)00097-9 [pii]
LID - 10.1016/j.htct.2022.06.009 [doi]
AB  - INTRODUCTION: Immunoglobulin represents the main therapy for patients with inborn 
      errors of immunity (IEI) and it is a safe procedure, but adverse events (AEs) can 
      occur with variable frequencies. OBJECTIVE: To evaluate the frequency of 
      immediate AEs to intravenous immunoglobulin (IVIG) regular therapy in a pediatric 
      cohort with IEI after a pre-IVIG infusion protocol. METHODS: This was a 
      longitudinal study from 2011 to 2019 at a tertiary pediatric hospital in Brazil. 
      RESULTS: A total of 1736 infusions were studied in 70 patients with IEI, 46 
      (65.7%) of whom were males and whose median age was 5.8 years old (range: 6 mo - 
      18 yo). Seven different brands of IVIG were used with the median loading dose of 
      0.57g/kg (range: 0.23 - 0.88g/Kg). According to the protocol, pre-medication and 
      step-up infusion rate, were performed in 1305 (75.2%) infusions. Immediate AEs 
      were noted in 10 children (14.3%) and in 22 (1.2%) infusions. Skin reactions 
      (rash or urticaria) were the most common AE with 14 episodes (0.8% of all 
      infusions). Almost all AEs were mild (19/86.4%), with no severe ones being 
      observed. The majority of the AEs (81.8%) was identified at a 0.04ml/kg/min 
      infusion rate. Gender, age at first infusion, presence of infection on the 
      infusion day and change of the IVIG brand were evaluated and none of them were 
      associated with AEs. CONCLUSION: The low frequency of immediate AEs in children 
      with IEI highlights the safety and tolerability of intravenous immunoglobulin 
      replacement with the procedures established at our center.
CI  - Copyright (c) 2022 Associacao Brasileira de Hematologia, Hemoterapia e Terapia 
      Celular. Published by Elsevier Espana, S.L.U. All rights reserved.
FAU - Antunes, Thales Silva
AU  - Antunes TS
AD  - Hospital da Crianca de Brasilia Jose Alencar (HCB), Brasilia, DF, Brazil. 
      Electronic address: thalesilvantunes@hotmail.com.
FAU - Melo, Karina Mescouto
AU  - Melo KM
AD  - Hospital da Crianca de Brasilia Jose Alencar (HCB), Brasilia, DF, Brazil.
FAU - Valente, Claudia Franca Cavalcante
AU  - Valente CFC
AD  - Hospital da Crianca de Brasilia Jose Alencar (HCB), Brasilia, DF, Brazil.
FAU - Tavares, Fabiola Scancetti
AU  - Tavares FS
AD  - Hospital da Crianca de Brasilia Jose Alencar (HCB), Brasilia, DF, Brazil.
LA  - eng
PT  - Journal Article
DEP - 20220808
PL  - Brazil
TA  - Hematol Transfus Cell Ther
JT  - Hematology, transfusion and cell therapy
JID - 101725732
PMC - PMC10244234
OTO - NOTNLM
OT  - Adverse events
OT  - Immunoglobulin
OT  - Inborn errors of immunity
OT  - Primary immunodeficiency
COIS- Conflicts of interest The authors declare no conflicts of interest
EDAT- 2022/09/17 06:00
MHDA- 2022/09/17 06:01
PMCR- 2022/08/08
CRDT- 2022/09/16 22:06
PHST- 2022/02/06 00:00 [received]
PHST- 2022/05/04 00:00 [revised]
PHST- 2022/06/24 00:00 [accepted]
PHST- 2022/09/17 06:01 [medline]
PHST- 2022/09/17 06:00 [pubmed]
PHST- 2022/09/16 22:06 [entrez]
PHST- 2022/08/08 00:00 [pmc-release]
AID - S2531-1379(22)00097-9 [pii]
AID - 10.1016/j.htct.2022.06.009 [doi]
PST - ppublish
SO  - Hematol Transfus Cell Ther. 2023 Apr-Jun;45(2):253-258. doi: 
      10.1016/j.htct.2022.06.009. Epub 2022 Aug 8.